Home About us Current issue Ahead of Print Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 1792 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 
 

Table of Contents   
CASE REPORT  
Year : 2014  |  Volume : 25  |  Issue : 5  |  Page : 1062-1064
Chronic graft versus host disease and nephrotic syndrome


1 Department of Nephrology and Laboratory of Renal Pathology, LR00S001, Hôpital Charles Nicolle, Tunis, Tunisia
2 Department of Bone Transplantation, Tunis, Tunisia

Click here for correspondence address and email

Date of Web Publication2-Sep-2014
 

   Abstract 

Disturbed kidney function is a common complication after bone marrow transplantation. Recently, attention has been given to immune-mediated glomerular damage related to graft versus host disease (GVHD). We describe a 19-year-old woman who developed membranous glomerulonephritis after bone marrow transplantation (BMT). Six months later, she developed soft palate, skin and liver lesions considered to be chronic GVHD. Fifteen months after undergoing BMT, this patient presented with nephrotic syndrome. A renal biopsy showed mem­branous glomerulonephritis associated with a focal segmental glomerulosclerosis. She was started on corticosteroid treatment with good outcome.

How to cite this article:
Barbouch S, Gaied H, Abdelghani KB, Goucha R, Lakhal A, Torjemen L, Hamida FB, Abderrahim E, Maiz HB, HafedhHedri, Adel K. Chronic graft versus host disease and nephrotic syndrome. Saudi J Kidney Dis Transpl 2014;25:1062-4

How to cite this URL:
Barbouch S, Gaied H, Abdelghani KB, Goucha R, Lakhal A, Torjemen L, Hamida FB, Abderrahim E, Maiz HB, HafedhHedri, Adel K. Chronic graft versus host disease and nephrotic syndrome. Saudi J Kidney Dis Transpl [serial online] 2014 [cited 2021 Aug 2];25:1062-4. Available from: https://www.sjkdt.org/text.asp?2014/25/5/1062/139941

   Introduction Top


Graft versus host disease (GVHD) is a se­rious immunological complication of bone marrow transplantation (BMT) that results in significant morbidity and mortality. [1] It appears 100 days after transplantation, [2] and occurs when donor T lymphocytes react with foreign host cells. The pathophysiology is a complex process marked with host tissue damage caused by conditioning regimens, cytokines and cel­lular effectors through an immune response that includes donor T lymphocytes, antigen presenting cells and mechanisms of apoptosis. [3],[4],[5] Chronic kidney disease occurs in 20- 60% of BMT patients, and has been associated with the use of radiation and/or chemothera-peutic agents, GVHD and acute renal failure. [1]

Herein, we describe a patient who developed a late-onset nephropathy after BMT that was probably caused by GVHD.


   Case Report Top


A 19-year-old woman with chronic myelogenous leukemia underwent a BMT from her sister with identical HLA in September 2008. At that time, she received cytarabine/cyclo-phosphamide as a conditioner plus cyclos-porine as the GVHD prophylaxis.

In November 2008, she developed thrombotic microangiopathy; therefore, cyclosporine treatment was stopped and replaced with mycophenolate mofetil.

About six months later, she developed skin eruption, lichen of the soft palate, cytolytic and cholestatic hepatitis. The diagnosis of chronic graft versus host disease (cGVHD) was made. The eruption improved with steroid therapy, which was gradually tapered and stopped in December 2010.

In January 2011, the patient developed edema; her blood pressure was 110/60 mm Hg, urina-lysis showed proteinuria +++; hematuria +++, laboratory investigations revealed, WBC 5400, Hb: 12 g/dL, platelets: 140,000, proteinuria up to 10 g/day, serum proteins: 40 g/L, serum albumin: 17 g/L, gamma globulin: 2.8 g/L, creatinine: 36 μmol/L, cholesterol: 11.79 mmol/ L, triglyceride: 4.23 mmol/L, aspartate trans-aminase (AST): 17 U/L, alanine transaminase (ALT): 10 U/L, anti-nuclear antibodies: nega­tive and cryoglobulinemia: negative.

Her renal biopsy showed a specimen of renal cortical and medullar tissue that contained 35 glomeruli with two hyalinized glomeruli. The matrix expansion presented a mesangial hyper-cellularity. The glomerular basement mem­brane (GBM) was irregularly thinned with characteristic spikes. Granular deposition of IgG was seen with immunofluorescence.

The proteinuria decreased to 2.63 g/L after 45 days of corticosteroid treatment dosed at 1 mg/kg/d.


   Discussion Top


Our patient developed GVHD eight months after BMT. The main risk factor for cGVHD is HLA mismatch; [3] our patient had no HLA mismatch. Its incidence is also higher in older recipients, [4] gender mismatch (female donor to male recipient) [4] and allogeneic BMT.

The role of B cells in cGVHD is not well established. Several studies found 35 different antibodies to be more prevalent in cGVHD, but none of the studies have convincingly demonstrated that these antibodies contribute to the clinical manifestations of tissue injury in cGVHD. In addition, tissue injury via immune complexes or vasculitis are not prominent features of cGVHD. [6] Several studies have suggested a possible collaboration between B and T cells in the pathogenesis of cGVHD. This is in accordance with the fact that T-helper cells, via CD40 ligand expression, are necessary for immuno-globulin isotype switching. [6] Additionally, treat­ment with rituximab resulted in an incomplete response in a bullous pemphigoid-cGVHD patient. [7] But, when adding daclizumab, an anti-CD25 antibody, a complete clinical res­ponse in combination with a complete decrease in bullous pemphigoid titer was observed. [6]

The BMT-related nephropathies are rare and include acute renal failure (ARF), hemolytic uremic syndrome (HUS), nephrotic syndrome (NS) and chronic renal failure (CRF). These nephropathies can be divided into two groups according to the time of appearance: Early-onset and late-onset (before or 150 days after BMT, respectively). Drugs, especially cyclos-porine A (CsA), and infections are responsible for the early-onset nephropathy that manifests as ARF and HUS. Conversely, late-onset nephropathies mainly present as GVHD-rela-ted NS, CRF and irradiation-related nephro-pathy.

An association of glomerular disease with simultaneous GVHD was reported in 47% of the patients. [5] Membranous glomerulonephritis (MGN) is the most frequent glomerular mani­festation of chronic GVHD. Other reported forms of glomerulonephritis include minimal change disease (MCD), membranoproliferative glomerulonephritis, focal segmental glomerulo-sclerosis (FSGS), anti-neutrphil cytoplasmic antibodies (ANCA)-associated glomeruloneph-ritis, proliferative glomerulonephritis, and IgA nephropathy

Proximity of onset of the MGN to the cessa­tion of immunosuppression and concomitant GVHD suggest that the glomerular injury is immune mediated. The possible role of with­drawal of CsA administered as prophylaxis of GVHD should be considered, and after either its re-introduction or increased dosage, clinical improvement was achieved in many patients with MGN, as observed also in our patient.

The finding of FSGS has been reported in patients with interferon therapy and high dosage chemotherapy for chronic myeloid leukemia, which provides evidence that high-dosage chemotherapy alone may be sufficient to result in severe podocyte injury. [8]

The diversity of organ involvement, the chro­nic nature of the illness and the hematological and immunological dysfunction associated with the syndrome contribute to the difficulties in successfully treating cGVHD. Therapeutic op­tions included mostly steroids and cyclos-porine. [9],[10] Similar to idiopathic MCD, almost all patients achieved complete remission, and response was generally reached after 8-10 weeks of treatment. [2] However, concerning mem­branous nephropathy, prognosis does not seem so favorable: Only 27% achieved com-plete and 62% achieved partial remission. [11] Intra­venous immunoglobulin (IVIG) may be one of the choices when patients do not respond to multiple immunosuppressive interventions. In fact, IVIG, with its effects of anti-idiotypic regulation and inhibition of cytokines, can modulate or reduce the severity of acute GVHD. However, the role of IVIG therapy in the prevention and treatment of GVHD is still not well established. [12]

We conclude that our patient presented with MGN as a manifestation of GVHD. Immuno-suppression seems to play a major role in controlling the disease and prognosis is appa­rently favorable.

 
   References Top

1.Hingorani S. Chronic kidney disease in long-term survivors of hematopoietic cell trans­plantation: Epidemiology, pathogenesis, and treatment. J Am Soc Nephrol 2006; 17:1995-2005.  Back to cited text no. 1
[PUBMED]    
2.Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease: Clinical manifestation and therapy. Bone Marrow Transplant 2001;28:121-9.  Back to cited text no. 2
    
3.Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with metho-trexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998;92: 2303-14.  Back to cited text no. 3
    
4.Carlens S, Ringden O, Remberger M, et al. Risk factors for chronic graft-versus-host di­sease after bone marrow transplantation: A retrospective single centre analysis. Bone Marrow Transplant 1998;22:755-61.  Back to cited text no. 4
    
5.Brukamp K, Doyle AM, Bloom RD, Bunin N, Tomaszewski JE, Cizman B. Nephrotic Syn­drome after Hematopoietic Cell Transplan­tation: Do Glomerular Lesions Represent Renal Graft-versus-Host Disease? Clin J Am Soc Nephrol 2006;1:685-94.  Back to cited text no. 5
    
6.Kapur R, Ebeling S, Hagenbeek A. B-cell involvement in chronic graft-versus-host disease. Haematologica 2008;93:1702-11.  Back to cited text no. 6
    
7.Szabolcs P, Reese M, Yancey KB, Hall RP, Kurtzberg J. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant 2002;30:327-9.  Back to cited text no. 7
    
8.Au WY, Chan KW, Lui SL, Lam CC, Kwong YL. Focal segmental glomerulosclerosis and mesangial sclerosis associated with myelo-proliferative disorders. Am J Kidney Dis 1999; 34:889-93.  Back to cited text no. 8
    
9.Stylianou K, Stratakis S, Mavroeidi V, et al. Membranous nephropathy and lupus-like syndrome after hematopoietic cell transplan­tation: A case report. J Med Case Rep 2010; 4:303.  Back to cited text no. 9
    
10.Luo XD, Liu QF, Ning J, et al. Clinical analysis of late-onset nephrotic syndrome after allogenic hematopoietic stem cell transplan­tation. Zhonghua Yi Xue Za Zhi 2007;87: 3280-3.  Back to cited text no. 10
    
11.Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990;75:2459-64.  Back to cited text no. 11
    
12.Wang HH, Yang AH, Yang LY, et al. Chronic graft-versus-host disease complicated by neph-rotic syndrome. J Chin Med Assoc 2011;74: 419-22.  Back to cited text no. 12
    

Top
Correspondence Address:
Dr. Samia Barbouch
Department of Nephrology and Laboratory of Renal Pathology, LR00S001, Hôpital Charles Nicolle, Tunis
Tunisia
Login to access the Email id


DOI: 10.4103/1319-2442.139941

PMID: 25193909

Rights and Permissions




 

Top
   
 
 
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  
 


 
    Abstract
   Introduction
   Case Report
   Discussion
    References
 

 Article Access Statistics
    Viewed2752    
    Printed56    
    Emailed0    
    PDF Downloaded481    
    Comments [Add]    

Recommend this journal